361 related articles for article (PubMed ID: 24926734)
1. Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain.
Mercadante S; Porzio G; Adile C; Aielli F; Cortegiani A; Dickenson A; Casuccio A
Curr Med Res Opin; 2014 Oct; 30(10):2063-8. PubMed ID: 24926734
[TBL] [Abstract][Full Text] [Related]
2. Tapentadol in cancer pain management: a prospective open-label study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Adile C; Ficorella C; Giarratano A; Casuccio A
Curr Med Res Opin; 2012 Nov; 28(11):1775-9. PubMed ID: 23057488
[TBL] [Abstract][Full Text] [Related]
3. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids.
Mercadante S; Porzio G; Aielli F; Adile C; Verna L; Ficorella C; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):661-6. PubMed ID: 23540512
[TBL] [Abstract][Full Text] [Related]
4. The role of tapentadol as a strong opioid in cancer pain management: a systematic and critical review.
Mercadante S
Curr Med Res Opin; 2017 Nov; 33(11):1965-1969. PubMed ID: 28906155
[TBL] [Abstract][Full Text] [Related]
5. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
6. The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients.
Mercadante S; Porzio G; Aielli F; Ferrera P; Codipietro L; Lo Presti C; Casuccio A
Clin J Pain; 2013 Jan; 29(1):15-9. PubMed ID: 22510538
[TBL] [Abstract][Full Text] [Related]
7. Low morphine doses in opioid-naive cancer patients with pain.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Ficorella C; Verna L; Tirelli W; Villari P; Arcuri E
J Pain Symptom Manage; 2006 Mar; 31(3):242-7. PubMed ID: 16563318
[TBL] [Abstract][Full Text] [Related]
8. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
9. Addition of a second opioid may improve opioid response in cancer pain: preliminary data.
Mercadante S; Villari P; Ferrera P; Casuccio A
Support Care Cancer; 2004 Nov; 12(11):762-6. PubMed ID: 15206014
[TBL] [Abstract][Full Text] [Related]
10. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
11. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis.
Mercadante S; Fulfaro F; Casuccio A
Eur J Cancer; 2002 Jul; 38(10):1358-63. PubMed ID: 12091067
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
[TBL] [Abstract][Full Text] [Related]
13. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
[TBL] [Abstract][Full Text] [Related]
14. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain.
Bandieri E; Romero M; Ripamonti CI; Artioli F; Sichetti D; Fanizza C; Santini D; Cavanna L; Melotti B; Conte PF; Roila F; Cascinu S; Bruera E; Tognoni G; Luppi M;
J Clin Oncol; 2016 Feb; 34(5):436-42. PubMed ID: 26644526
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
[TBL] [Abstract][Full Text] [Related]
18. Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit.
Mercadante S; Prestia G; Ranieri M; Giarratano A; Casuccio A
Support Care Cancer; 2013 Jul; 21(7):1853-9. PubMed ID: 23400316
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
[TBL] [Abstract][Full Text] [Related]
20. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
